Assignee
BIOGEN MA INC
US·205 granted patents·235 pending applications·846 citations·filing 2010–2025
Top patents by PatentIndex Score
440 records- 0197US10335393B2Nuclear transport modulators and uses thereofBIOGEN MA INC·Filed 2017·Granted Jul 2, 2019·20 cites·12 claims
- 0297US10058535B2Nuclear transport modulators and uses thereofBIOGEN MA INC·Filed 2017·Granted Aug 28, 2018·24 cites·1 claims
- 0397US9717750B2Compositions and methods for modulation of SMN2 splicing in a subjectBIOGEN MA INC·Filed 2015·Granted Aug 1, 2017·26 cites·42 claims
- 0496US10968453B2Compositions for modulating SOD-1 expressionBIOGEN MA INC·Filed 2020·Granted Apr 6, 2021·3 cites·24 claims
- 0595US11571477B2Anti-VLA-4 antibodiesBIOGEN MA INC·Filed 2021·Granted Feb 7, 2023·2 cites·3 claims
- 0695USD797132SDisplay screen with graphical user interfaceBIOGEN MA INC·Filed 2015·Granted Sep 12, 2017·152 cites·1 claims
- 0794US10722497B2Nuclear transport modulators and uses thereofBIOGEN MA INC·Filed 2019·Granted Jul 28, 2020·3 cites·26 claims
- 0894US10444234B2Assay for JC virus antibodiesBIOGEN MA INC·Filed 2016·Granted Oct 15, 2019·10 cites·53 claims
- 0994US10233245B2Methods of treating inflammatory and autoimmune diseases with natalizumabBIOGEN MA INC·Filed 2017·Granted Mar 19, 2019·15 cites·19 claims
- 1094US9926559B2Compositions and methods for modulation of SMN2 splicing in a subjectBIOGEN MA INC·Filed 2014·Granted Mar 27, 2018·12 cites·10 claims
- 1193US11427577B2Inhibiting agents for Bruton's tyrosine kinaseBIOGEN MA INC·Filed 2021·Granted Aug 30, 2022·2 cites·9 claims
- 1293US9650430B2Methods of treating autoimmune diseases using a B-cell maturation antigen (BCMA)BIOGEN MA INC·Filed 2014·Granted May 16, 2017·8 cites·10 claims
- 1393US9598484B2Human anti-tau antibodiesBIOGEN MA INC·Filed 2013·Granted Mar 21, 2017·18 cites·182 claims
- 1492US10961237B2Inhibiting agents for Bruton's tyrosine kinaseBIOGEN MA INC·Filed 2019·Granted Mar 30, 2021·4 cites·6 claims
- 1592US10793856B2Compositions for modulating Tau expressionBIOGEN MA INC·Filed 2017·Granted Oct 6, 2020·9 cites·58 claims
- 1692US10677803B2Method of assessing risk of PMLBIOGEN MA INC·Filed 2018·Granted Jun 9, 2020·10 cites·16 claims
- 1792US10669546B2Compositions for modulating SOD-1 expressionBIOGEN MA INC·Filed 2019·Granted Jun 2, 2020·4 cites·28 claims
- 1892US10617677B2Nuclear transport modulators and uses thereofBIOGEN MA INC·Filed 2018·Granted Apr 14, 2020·3 cites·18 claims
- 1992US10436802B2Methods for treating spinal muscular atrophyBIOGEN MA INC·Filed 2015·Granted Oct 8, 2019·13 cites·20 claims
- 2092US10385341B2Compositions for modulating SOD-1 expressionBIOGEN MA INC·Filed 2015·Granted Aug 20, 2019·9 cites·24 claims
- 2192US10166250B2Bicyclic aryl sphingosine 1-phosphate analogsBIOGEN MA INC·Filed 2017·Granted Jan 1, 2019·9 cites·11 claims
- 2292US9790229B2Bruton's tyrosine kinase inhibitorsBIOGEN MA INC·Filed 2016·Granted Oct 17, 2017·11 cites·21 claims
- 2392US9572824B2Bicyclic aryl sphingosine 1-phosphate analogsBIOGEN MA INC·Filed 2015·Granted Feb 21, 2017·10 cites·14 claims
- 2491US11753668B2Copper supplementation for control of glycosylation in mammalian cell culture processBIOGEN MA INC·Filed 2022·Granted Sep 12, 2023·3 cites·16 claims
- 2591US11591595B2Compositions for modulating Tau expressionBIOGEN MA INC·Filed 2020·Granted Feb 28, 2023·2 cites·34 claims
- 2691US10702603B2Methods and compositions for inactivating enveloped virusesBIOGEN MA INC·Filed 2018·Granted Jul 7, 2020·9 cites·15 claims
- 2791US10335485B2Anti-VLA-4 antibodiesBIOGEN MA INC·Filed 2017·Granted Jul 2, 2019·7 cites·6 claims
- 2891US10119976B2Method of assessing risk of PMLBIOGEN MA INC·Filed 2014·Granted Nov 6, 2018·10 cites·26 claims
- 2991US10081619B2Biaryl inhibitors of bruton's tyrosine kinaseBIOGEN MA INC·Filed 2017·Granted Sep 25, 2018·7 cites·4 claims
- 3091US9944622B2Pyrimidinyl tyrosine kinase inhibitorsBIOGEN MA INC·Filed 2016·Granted Apr 17, 2018·8 cites·16 claims
- 3191US9827258B2Bicyclic aryl sphingosine 1-phosphate analogsBIOGEN MA INC·Filed 2017·Granted Nov 28, 2017·8 cites·10 claims
- 3291US9809577B2Biaryl inhibitors of Bruton's tyrosine kinaseBIOGEN MA INC·Filed 2014·Granted Nov 7, 2017·12 cites·2 claims
- 3391US9186367B2Bicyclic aryl sphingosine 1-phosphate analogsBIOGEN MA INC·Filed 2014·Granted Nov 17, 2015·15 cites·14 claims
- 3490US10759783B2Biaryl inhibitors of Bruton'S tyrosine kinaseBIOGEN MA INC·Filed 2018·Granted Sep 1, 2020·3 cites·11 claims
- 3590US10227341B2Inhibiting agents for bruton's tyrosine kinaseBIOGEN MA INC·Filed 2018·Granted Mar 12, 2019·8 cites·26 claims
- 3690US9994609B2Hydrophobic interaction protein chromatography under no-salt conditionsBIOGEN MA INC·Filed 2014·Granted Jun 12, 2018·12 cites·17 claims
- 3790US2025282883A1Anti-bcma antibodiesBIOGEN MA INC·Filed 2024·Application pending·0 cites
- 3889US11116911B2Injector lockout prevention deviceBIOGEN MA INC·Filed 2017·Granted Sep 14, 2021·10 cites·4 claims
- 3989US10189829B2Inhibiting agents for Bruton's tyrosine kinaseBIOGEN MA INC·Filed 2018·Granted Jan 29, 2019·6 cites·8 claims
- 4088US12392784B2Method of assessing risk of PMLBIOGEN MA INC·Filed 2024·Granted Aug 19, 2025·0 cites·26 claims
- 4188US10844416B2Manganese supplementation for control of glycosylation in mammalian cell culture processBIOGEN MA INC·Filed 2016·Granted Nov 24, 2020·5 cites·21 claims
- 4288US10563163B2Cross-scale modeling of bioreactor cultures using Raman spectroscopyBIOGEN MA INC·Filed 2015·Granted Feb 18, 2020·12 cites·21 claims
- 4388US10188732B2Methods and compositions for inactivating enveloped virusesBIOGEN MA INC·Filed 2013·Granted Jan 29, 2019·11 cites·14 claims
- 4488US9771326B2S1P and/or ATX modulating agentsBIOGEN MA INC·Filed 2013·Granted Sep 26, 2017·6 cites·11 claims
- 4588US9522174B2Stable liquid interferon beta formulationsBIOGEN MA INC·Filed 2014·Granted Dec 20, 2016·4 cites·15 claims
- 4687US11827702B2Anti-transferrin receptor antibodies and uses thereofBIOGEN MA INC·Filed 2022·Granted Nov 28, 2023·1 cites·11 claims
- 4787US11083791B2Anti-VLA-4 antibodiesBIOGEN MA INC·Filed 2019·Granted Aug 10, 2021·4 cites·22 claims
- 4887US10705095B2Methods and products for evaluating an immune response to a therapeutic proteinBIOGEN MA INC·Filed 2017·Granted Jul 7, 2020·2 cites·22 claims
- 4987US2024238326A1Compositions and methods for modulation of smn2 splicing in a subjectBIOGEN MA INC·Filed 2023·Application pending·0 cites
- 5087US2024051917A1Heterocyclic sulfonamides, uses and pharmaceutical compositions thereofBIOGEN MA INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 440 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →